Table 3.
Mean changes in weight, fasting plasma glucose and fasting insulin at end of study year one for each quartile for metformin and placebo groups
| Weight change (kg) | Glucose change (mmol/l) | Fasting insulin change (pmol/l) | |||
|---|---|---|---|---|---|
| Placebo | Metformin | Placebo | Metformin | Placebo | Metformin |
| −8.1 (164) | −7.7 (346) | −0.74 (180) | −0.82 (303) | −125.7 (195) | −118.8 (301) |
| −2.2 (227) | −2.4 (281) | −0.29 (248) | −0.31 (293) | −30.6 (209) | −30.6 (269) |
| +0.2 (289) | +0.05 (226) | +0.02 (258) | +0.02 (248) | +9.7 (263) | +9.0 (229) |
| +3.8 (346) | +3.5 (162) | +0.69 (340) | +0.58 (171) | +104.2 (332) | +91.0 (191) |
Number of individuals in each quartile is given in parenthesis. Quartiles were determined for entire study population with baseline normal ALT (<95% NHANES specific data). Thus mean changes in weight, fasting plasma glucose and fasting insulin are similar for each quartile, but due to the effect of metformin, numbers of individuals per treatment group are different for each quartile. For each weight and glucose quartiles, n = 2,041; for the insulin quartiles n = 1,979 due to missing baseline or 1-year insulin concentrations.